"Designing Growth Strategies is in our DNA"
Facial injectables, also known as dermal or facial fillers, are products composed of collagen, hyaluronic acid and calcium hydroxylapatite that revive facial skin by performing a number of activities such as the removal & reduction of wrinkles, uplifting of scar depressions, improving lips and reduction of the volume of soft-tissue with facial injections. Other factors contributing to the deterioration of the skin include increased exposure to the sun, smoking and lack of exercise. The success of the procedure of facial injectables depends on a number of factors such as the healthiness of the skin, expertise of the health care provider, kind of filler used amongst others.
The growth of the global facial injectables market is attributed to a number of factors such as the increasing demand for minimally invasive cosmetic procedures, increasing affordability, rising demand for aesthetic beauty, increasing longevity of the facial injectables, increasing demand amongst the geriatric population and lesser recovery time post procedures. According to the new statistics by the American Society of Plastic Surgeons (ASPS), that there were 15.4 million minimally invasive procedures in the U.S. in 2016, with Botulinum Toxin Type A constituting about more than 7 million of these procedures. These factors are expected to drive the growth of the global facial injectables market.
To gain extensive insights into the market, Request for Customization
The factors limiting the growth of the global facial injectables market include the associated side effects such as allergies, the formation of tiny bumps, and in rarer cases may induce paralysis and blindness. Inadequate reimbursement policies, the presence of counterfeit products and the dearth of registered practitioners are some of the other factors restraining the growth of the global facial injectables market.
Some of the major companies that are present in the global Facial injectables market are ALLERGAN, Nestlé Skin Health, Merz Pharma, Ipsen Pharma, Anika Therapeutics, Inc., Bloomage BioTechnology Corporation Limited, Merz Pharma and others.
SEGMENTATION | DETAILS |
By Product | · Botulinum Toxin Type A · Hyaluronic Acid · Collagen · Particle Polymer Fillers · Poly-L-Lactic Acid · Calcium Hydroxylapatite |
By Application | · Wrinkle Reduction · Facelift · Lip Enhancement · Others |
By End User | · Hospitals · Specialty clinics · Others |
By Geography | · North America (USA and Canada) · Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe) · Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific) · Latin America (Brazil, Mexico and Rest of Latin America) · Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa) |
Specialty clinics among the end users are projected to hold a considerable share of the global facial injectables market due to modernization more population moving towards the facelift and antiwrinkle surgeries.
Regulatory scenario for key countries
Reimbursement Scenario for key countries
Procedure Statistics, By Key Procedures
Recent industry developments such as partnerships, mergers, and acquisitions
North America accounts for the largest share in the global market due to the increasing demand for minimally invasive procedures, demand for increasing aesthetics such as anti-aging treatments, the high prevalence of skin disorders, established healthcare system and availability of cost-effective procedures. The Asia Pacific is the fastest emerging market due to the increasing demand for aesthetic procedures, developing healthcare system, declining in social taboo with respect to aesthetic procedures and availability of affordable procedures. According to World Health Organization, in 2016, approximately 30 countries in Africa and Asia Pacific region had a shortfall of facial Injectables, indicating the huge potential for these systems in these regions and is expected to drive the growth of facial injectables in the forecast period.
Key Industry Developments |
· In April 2019, Allergan plc., launched Juvederm VOLUX at the 17th Aesthetic & Anti-Aging World Congress (AMWC) in Monaco. Juvederm VOLUX is the latest innovation in Allergan's extensive range of Juvederm facial fillers. · In April 2019, Merz Pharma launched of Belotero Revive, a dermal filler product containing a unique combination of hyaluronic acid (HA) and glycerol, specially designed for the improve hydration, elasticity and firmness of the skin and to address the appearance of fine lines. |